Should you buy Krystal Biotech stock now?
The technical signal for Krystal Biotech is currently NEUTRAL. Krystal Biotech trades at $324.24 as of 8/6/2026. The overall technical signal is: Hold. The technical analysis shows the following: MACD is negative (bearish trend) at -3.300 with falling momentum (signal: 0.699); RSI is at 43.3 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $382.86 points to 18.1% upside. This is a technical observation based on current data, not investment advice.
What is the price target for Krystal Biotech stock?
The average analyst price target for Krystal Biotech is $382.86. The current price is $324.24, which gives an upside of 18.1%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $344.57 and $421.15.
Is Krystal Biotech a dividend stock?
No, Krystal Biotech does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Krystal Biotech stock?
Krystal Biotech is rated as a stock with moderate risk. the annual standard deviation is 39.3%, which classifies the stock as moderate risk.
Is Krystal Biotech overvalued?
No, Krystal Biotech is considered undervalued based on the analyst price target (18.1% upside). Krystal Biotech has the following valuation ratios: a P/E ratio of 41.9 (highly valued), a P/S ratio of 21.8, a P/B ratio of 7.9. The analyst price target suggests that the stock is undervalued by 18.1%.
Is Krystal Biotech overbought?
No, Krystal Biotech is not overbought. RSI is at 43.3 (neutral zone). The technical indicators show: RSI is at 43.3 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 6.2% below the 20-day average (short-term downtrend). In addition, MACD is negative with falling momentum (bearish).
When is the next Krystal Biotech earnings report?
The date of the next earnings report for Krystal Biotech has not been published yet. Check the company's investor calendar for updates.
Is Krystal Biotech shorted?
Yes, Krystal Biotech is shorted with 19.5% of the free float sold short. This is a very high level of short selling, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains. Data is updated daily based on official filings with the SEC.
Are insiders buying Krystal Biotech stock?
No, insiders are not buying Krystal Biotech shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 4 sales. On a net basis, 740,815 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 32,595,959 $ sold. Active sellers include Thomas John Charles, Krishnan Suma, Krishnan Krish S and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Krystal Biotech a good stock?
Based on our total score, Krystal Biotech is rated as a good stock with a total score of 61 out of 100. The stock scores above average on value, quality and momentum – it is among the top 39% in our database. The score is made up of Value: 19/100, Quality: 90/100, Momentum: 73/100. In addition: analysts see 18.1% upside to the price target; technical signal: Hold. Whether Krystal Biotech is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Krystal Biotech stock?
The outlook for Krystal Biotech based on current data: the average analyst price target is $382.86 (+18.1%); the P/E ratio is 41.9 (high – the market expects growth). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Krystal Biotech stock falling?
Krystal Biotech is falling right now. The technical indicators show: the price is 6.2% below the 20-day average; MACD is negative with falling momentum (bearish signal); short interest is 19.5% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Krystal Biotech go?
The average analyst price target for Krystal Biotech is $382.86, which corresponds to a potential gain of 18.1% from the current price of $324.24. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Krystal Biotech fall?
We lack enough history to give a specific floor for Krystal Biotech. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Krystal Biotech do?
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-V... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Krystal Biotech as an investment.
Did Krystal Biotech raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Krystal Biotech. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Krystal Biotech making money or losing money?
Yes, Krystal Biotech is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 54.8% — which is excellent. The operating margin (profit before interest and taxes) is 49.0%. At a P/E ratio of 41.9, you currently pay 41.9 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Krystal Biotech go bankrupt?
The bankruptcy risk of Krystal Biotech is rated as low. Altman Z2 (a model for assessing financial distress) is 15.32 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 5 — which is average. Debt relative to equity is 12% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Krystal Biotech have a lot of debt?
No, Krystal Biotech has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 12%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
